Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics' stock price increased by 289.29% in the past six months, reaching $1.67 as of January 9, 2026. Q2 2025 earnings exceeded analyst expectations, while Q3 2025 earnings missed estimates, leading to a stock decline. The company announced progress in its Phase 1 study of OV329 and plans for OV350, but paused the Phase 2 study for OV888/GV101. Shareholder dilution occurred with an 83.3% increase in total shares outstanding. A new major risk related to share price stability was identified. Analysts gave Ovid Therapeutics a consensus "Buy" rating with an average price target of $3.88.

There is no clear indication of demand seasonality for Ovid Therapeutics' products, as the company focuses on developing therapies for rare neurological disorders and epilepsies, which typically address ongoing medical needs rather than seasonal demand fluctuations.

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for rare neurological and psychiatric diseases, particularly those with CNS hyperexcitability, aiming to reduce seizures and improve the lives of affected individuals. The company operates in the biotechnology and pharmaceutical industries, specializing in neurodevelopmental disorders, epilepsy, and rare genetic neurological conditions. Ovid's pipeline includes OV101 (Gaboxadol) for FXTAS and Angelman Syndrome, OV329 for treatment-resistant seizures, OV4071 as an oral direct activator of KCC2 for multiple CNS disorders, OV350 as a direct activator of the KCC2 transporter, OV888 (GV101) for cerebral cavernous malformations, and Soticlestat (formerly OV935) for Dravet and Lennox-Gastaut syndromes, developed in collaboration with Takeda Pharmaceutical Company Limited.

Ovid Therapeutics Inc. is headquartered in New York, NY, United States. The company engages with patient advocacy groups, key opinion leaders, and regulatory bodies to maintain a market presence. Ovid has international reach through strategic collaborations, including an agreement granting regional rights for soticlestat to a leading pharmaceutical company for select Asian markets.

Ovid Therapeutics has received positive sentiment from analysts, with a consensus "Buy" rating and several "Outperform" recommendations, highlighting positive KCC2 platform progress and underappreciated pipeline optionality. However, the disclosure of a $1.8 million fraudulent transfer due to a business email compromise in a November 2024 quarterly report could have affected the company's reputation.

Ovid Therapeutics Inc. has a mixed ownership structure including institutional, insider, and retail investors. Institutional investors hold approximately 72.24% of the company's stock. Insiders own about 17.69% of the stock, while public companies and individual investors hold the remaining shares. Major institutional owners include Takeda Pharmaceutical Co Ltd, Vanguard Group Inc, and Affinity Asset Advisors, LLC.